- Home
- FDS vs KRYS Comparison
FDS vs KRYS Comparison
Compare FDS & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FDS | KRYS |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | United States |
| Employees | 6258 | 295 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 10.1B |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FDS | KRYS |
|---|---|---|
| Price | $264.01 | $344.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $284.80 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 814.3K | 548.4K |
| Earning Date | 03-31-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | 11.79 | ★ 128.00 |
| EPS | ★ 11.16 | 1.83 |
| Revenue | ★ $1,435,351,000.00 | $389,130,000.00 |
| Revenue This Year | $7.16 | $38.74 |
| Revenue Next Year | $5.55 | $32.53 |
| P/E Ratio | ★ $23.70 | $199.26 |
| Revenue Growth | 6.31 | ★ 33.94 |
| 52 Week Low | $185.00 | $130.50 |
| 52 Week High | $398.50 | $382.54 |
Technical Indicators
Market Signals| Indicator | FDS | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 48.69 |
| Support Level | $245.31 | $246.17 |
| Resistance Level | $274.72 | $382.33 |
| Average True Range (ATR) | 11.11 | 18.24 |
| MACD | 1.01 | -0.46 |
| Stochastic Oscillator | 40.20 | 53.10 |
Price Performance
Historical ComparisonAbout FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for over 80% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.